Business
K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate Demonstrates Tumor-Selective Pharmacokinetics, Extensive Intratumoral Distribution and Superior Efficacy in Non-Clinical Animal Models
Kowa Company, Ltd. (Headquarters: Nagoya, Aichi Prefecture, Japan), today announced an upcoming presentation of non-clinical data for K‑679, its novel antibody drug-loaded unimicelle conjugate (ADUC) with unprecedented drug loading capacity. The compound, developed using Kowa's proprietary micelle technology, has demonstrated tumor-selective pharmacokinetics, extensive intratumoral distribution, and superior efficacy in EGFR-expressing solid tumors compared to conventional antibody drug conjugat
About this update from Kowa Co. Ltd.
[{"type":"text","content":"NAGOYA, Japan, April 6, 2026 /PRNewswire/ -- Kowa Company, Ltd. (Headquarters: Nagoya, Aichi Prefecture, Japan), today announced an upcoming presentation of non-clinical data for K‑679, its novel antibody drug-loaded unimicelle conjugate (ADUC) with unprecedented drug loading capacity. The compound, developed using Kowa's proprietary micelle technology, has demonstrated tumor-selective pharmacokinetics, extensive intratumoral distribution, and superior efficacy in EGFR-expressing solid tumors compared to conventional antibody drug conjugates (ADCs). The data will be presented at The American Association for Cancer Research (AACR) Annual Meeting 2026 to be held in San Diego, California, from April 17 to 22, 2026.","length":745,"tagName":"p"},{"type":"image","alt":"Kowa Company, Ltd. (PRNewsFoto/Kowa Research Institute, Inc.)","displaySize":"","headline":null,"caption":"Kowa Company, Ltd. (PRNewsFoto/Kowa Research Institute, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":177,"url":"https://media.zenfs.com/en/cnwgroup.com/95bdc93b2c39224b9502326b20d61357"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sgUUM5GvKfrHsBkdvT2lXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTMxMg--/https://media.zenfs.com/en/cnwgroup.com/95bdc93b2c39224b9502326b20d61357","width":400,"height":177}},"href":"https://mma.prnewswire.com/media/320297/kowa_research_institute_inc_logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Presentation DetailsPresentation Title: Selective intratumoral distribution and post-T-DXd activity of K-679, an ultra-high-DAR EGFR-targeted antibody drug-loaded unimicelle conjugate (ADUC)Session Title: Antibody Technologies and Platforms 2Presentation Date and Time: April 21, 2026, 9:00 a.m. – 12:00 p.m. CST (10:00 a.m. – 1:00 p.m. ET)Poster Number: 4396Presenter: Hideo Yoshida","length":388,"tagName":"p"},{"type":"text","content":"The abstract of the presentation is available atAACR Annual Meeting 2026 Itinerary Planner | Presentation","length":106,"tagName":"p"},{"type":"text","content":"More information about the AACR Annual Meeting 2026 can be found on the event website at the following link: AACR Annual Meeting 2026 | Meetings | AACR","length":151,"tagName":"p"},{"type":"text","content":"About K-679K-679 is an Antibody Drug-loaded Unimic...